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The human gut commensal microbiota forms a complex population of microorganisms that
survive by maintaining a symbiotic relationship with the host. Amongst the metabolic
beneﬁts it brings, formation of adaptive immune system and maintenance of its homeo-
stasis are functions that play an important role. This review discusses the integral elements
of commensal microbiota that stimulate responses of different parts of the immune system
and lead to health or disease. It aims to establish conditions and factors that contribute to
gut commensal microbiota's transformation from symbiotic to antibiotic relationship with
human. We suggest that the host-microbiota relationship has been evolved to beneﬁt both
parties and any changes that may lead to disease, are not due to unfriendly properties of the
gut microbiota but due to host genetics or environmental changes such as diet or infection.
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It is now become evident that microbiota plays an essential role
in the function, induction, and training of the host immune
system. As a consequence, the immune system has evolved
strategies to maintain this symbiotic relationship with a large
number of diverse microbes. An average human gut contains
approximately 1014 bacteria, most of which cannot be cultured.
The vast majority of these commensals fall into one of twoPeer review under the responsibility of the Lithuanian University of H
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has been approximated that these bacteria contain over 100
times more genes than a whole human genome [1]. Many of
these genes directly inﬂuence host metabolic pathways and
provide the host with nutrients that otherwise it would not
receive [2]. Therefore, the gut commensals differ from patho-
gens in that they are allowed to co-exist due to the beneﬁts they
provide to the host; therefore the host does not try to eradicate
them from the mucosa, but still maintains the ability to actively
ﬁght pathogens.ealth Sciences.
s@gmail.com (N. Malys).
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m e d i c i n a 5 1 ( 2 0 1 5 ) 6 9 – 7 570Germ free (GF) mice are a tool often used to see the effects of
ablated microbiota on host metabolic and immune function
[3]. These mice also enable one to re-colonize the gut with a
speciﬁc species of commensal bacteria to isolate its effects.
This review will discuss the gut commensal microbiota
interactions with the host immune system, focusing on the
responses each part of innate and adaptive immune system
elicits. These responses may be beneﬁcial for the immune
system, since they enhance immune system's ability to ﬁght
pathogens and maintaining the composition of gut microbiota.
However, the responses can be unwanted since they may lead
to local inﬂammatory disorders, such as inﬂammatory bowel
disease (IBD) or autoimmune disease away from the gut [4].
This review will also attempt to juxtapose recent evidence on
gut commensal interaction with the host to establish what
contributes to switching from symbiosis to antibiosis.
2. Commensal microbiota affects infection
Composition of gut commensal organisms is greatly affected
when one is subjected to antibiotic treatment [5–7]. This
change in composition has been associated with pathogenic
infections of the gut [8,9]. Closely related species of pathogenic
bacteria that are commensal in the gut seem to tolerate their
related pathogenic bacteria colonization [10]. Therefore, it is
safe to say that speciﬁc microbial species dictate pathogenic
microbial colonization.
Even though, certain microbiota permits colonization of
pathogens, some can limit pathogenic bacterial growth.
Salmonella typhimurium induces inﬂammation which changes
microbial composition and suppresses their growth [11].
Avirulent S. typhimurium does not cause colitis and fails to
outcompete the microbiota unless inﬂammation is induced.
IL-10 knockout mice, a model of IBD, allow the pathogen to
overcome colonization resistance. However, transferring
normal gut ﬂora to S. typhimurium infected gut allows the
mice to recover and eliminate the pathogen [12]. The process
occurs in the absence of antibody response that clear the
pathogen in the secondary infection, thus clearance results as
a direct commensal microbiota pressure.
3. Innate responses
Intestinal epithelial cells (IECs) form a barrier that protects the
host from bacterial invasion. In addition to acting as a physical
barrier, they perform a role in the immune cell regulation via
expressing receptors for microbial-associated molecular pat-
tern (MAMPs). Activation of these receptors leads to down-
stream cascades, which affect the inﬂammatory status of IECs.
Apical expression of toll-like receptor 9 (TLR9) is involved in
immune homeostasis [7]. Activation of TLR9 on the apical
membrane of IECs leads to partial activation of nuclear factor
kappa-light-chain-enhancer of activated B cells (NFkB) with-
out stimulating the release of pro-inﬂammatory cytokines.
Apical introduction of CpG sites (where cytosine nucleotide
occurs next to a guanine nucleotide) of gut commensals
reduces the pro-inﬂammatory cytokine release when baso-
lateral TLR9 receptors are activated in IECs [13]. Protectiveeffects of microbiota can also be evidenced by Lactobacillus
casei, a common probiotic, inducing anti-inﬂammatory effects
through inhibition of NFkB pathway via stabilization of IkBa
during Shigella ﬂexneri infection, which ameliorates the disease
symptoms [14].
Short chain fatty acids (SCFA) are produced by ﬁber
carbohydrate fermentation in the gut by Bacteroides and
Clostridium species within the human gut [15]. Butyrate, one
of the products of ﬁber fermentation, provides a signal for
inhibition of pro-inﬂammatory cytokine expression in the IECs
that involve inhibition of NFkB pathway [16]. Moreover, butyrate
induces other protective mechanisms, such as production of
mucin and antimicrobial peptides, as well as increases
expression of tight junction proteins strengthening the epithe-
lial barrier [17]. Lower butyrate levels have been associated with
inﬂammatory bowel disease (IBD) such as Crohn's disease [16].
This shows that speciﬁc gut microbiota is important in keeping
the unwanted organisms in check as well as preventing
development of autoimmune disease, such as IBD.
It is important to point out that the host immune mediators
play a signiﬁcant role in controlling the microbiota. Changing
part of the immune control system alters the gut ﬂora
composition. The effects of dysbiosis have been illustrated by
the mice lacking Toll-like receptor 5 (TLR5) [18]. These mice are
highly predisposed to type 2 diabetes and cardiovascular
disease due to developed obesity. This metabolic syndrome is
caused by the altered balance of Firmicutes and Bacteroidetes,
which has been shown by transplanting the gut ﬂora from the
knockout mice into the wild-type, leading to development of the
metabolic syndrome [18]. Altered host mechanisms of immune
regulation have an impact on gut commensal composition and
in this way cause the disease. However, under normal
conditions the dysbiosis would be unlikely to occur and would
not lead to disease.
A new population of innate cells that are of lymphoid origin
has been identiﬁed recently. Not much is known about the
interactions of these cells with the gut commensals. However,
it seems that they can respond to direct and indirect actions of
gut commensals to elicit inﬂammatory and barrier strength-
ening responses [19]. These cells produce a great variety of
proinﬂammatory cytokines in response to activation through
TLR and other receptors limited to innate lymphoid cells [20].
Therefore, it is possible to speculate that responses of these
cells to gut microbiota affect immune homeostasis.
4. Adaptive responses
4.1. Th17 cells
T-cell responses have been shown to be dependent on the gut
commensal composition. Germ-free mice tend to have dimin-
ished T helper 1 and 17 cells (Th1 and Th17) responses but
maintained or increased CD4(+) T regulatory cells (T(regs))
frequency [21]. It has been found that segmented ﬁlamentous
bacteria (SFB) play an important role in inducing intestinal Th17
cells. These bacteria adhere to the surface of the intestine,
possibly contributing to their active sampling by the dendritic
cells and the strong induction of Th17 cells [22]. This has been
conﬁrmed by increased expression of interleukin 17 and 22
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been elucidated by the same study that Th17 differentiation is
mediated by the induced serum amyloid A in gnotobiotic mice
colonized with SFB [23]. Induction of Th17 cells can be beneﬁcial
when ﬁghting against pathogenic bacteria. SFB colonization
protects the mice from Citrobacter rodentium infection by
reducing their growth through stimulation of Th17 cells, which
suggests that the commensals are involved in enhancing barrier
function of the gut. Although experiments were done in mice, it
is generally believed to be transferable to humans, since the
presence of SFB 16sRNA has been detected not only in humans
but also across a wide range of vertebrae species [24].
Although, SFB seem to confer a protective function, in the
case of subjects with immune deﬁciencies, SFB induction of
Th17 has been associated with autoimmune diseases, such
autoimmune arthritis, where mice colonized with SFB had more
auto reactive antibodies compared to GF mice [25], and
experimental autoimmune encephalomyelitis (EAE) [26], a
mouse model for human multiple sclerosis. In each model,
mice have been bred to develop a genetic alteration which
increases a susceptibility to a speciﬁc autoimmune disease. The
disease progression and severity is then compared across each
strain with different groups subjected to different microbiota
conditions [27]. This allows for the recognition of the effects of
speciﬁc commensals on progression of a speciﬁc disease.
Whether induction of Th17 cells is beneﬁcial or detrimental is
not fully understood. Alterations in IL-1b and IL-23 molecules
have been recognized as factors in developing autoimmune
disease [28,29]. It seems that it is the combination of Th17
inducing microbiota and host factors that contribute to the
disease state.
However, Th17 pro-inﬂammatory cells have been shown,
using model of tolerance by CD-speciﬁc antibodies in the
mouse model of sepsis, to be redirected and controlled in the
small intestine [30]. These regulatory Th17 have an anti-
inﬂammatory cytokine proﬁle with IL-10 being the major
player [31]. Conversion of Th17 could mean that their
induction by microbiota may not be the main driving force
for the disease and that Th17 cells could in fact greatly
contribute to the regulation of immune responses.
4.2. T-regulatory cells
The proportion of CD4(+) T regulatory cells, which express
the Foxp3 transcription factor, is much larger in the colonic
mucosa than in other connective tissues or organs [32]. In
the GF mice the proportion and the absolute numbers of T
(regs) in the colonic mucosa of the colon are reduced.
However, the number of T(regs) in the small intestine
remains unchanged [32] and it can be induced by a mixture
of Clostridia strains from human microbiota [33,34], leading
to believe that microbiota play an important role in T(reg)
cell induction.
A considerably important studies on adaptive immune
system education has been conducted recently [35,36]. They
showed that normal commensal microbiota in the mice
intestine generated a speciﬁc group of T(reg) cells, limited to
the gut. The T-cell antigen receptors (TCR) present in these T
(reg) cell populations seemed to be reactive to speciﬁc
commensal antigens. Creation of retroviral bone marrowchimeras and a TCR transgenic line showed that normal gut
ﬂora is essential for the induction of colonic T(reg) cells from
naive T-cells. Lastly, using adoptive transfer of microbiota
reactive effector T-cells, into Rag/ mice that have induced
colitis illustrates the pathological consequences of T-cell
recognition of gut commensals, under proinﬂammatory con-
ditions [35].
It has been argued that certain commensal bacteria can
induce CD4+ T-cell differentiation into T(reg) cells. One of the
well-researched examples has been the spore-forming Clostridi-
um species that belongs to clusters XIVa and IV [32]. Colonizing
GF mice with specially isolated Clostridium species from the
normally grown mice induced T(reg) cell differentiation. These
T(reg) cells are helios-negative, thus are induced in the colon
rather than matured in the thymus [37]. Furthermore, Clostridi-
um-induced T(reg) cells express high levels of IL-10, which is an
important cytokine for maintenance of immune homeostasis
[32,38]. Mice were also subjected to dextran sodium sulphate
(DSS)-mediated colitis, which made it possible to show that
inoculations with Clostridium spp. reduced allergic and inﬂam-
matory diseases progression [32]. Therefore, speciﬁc gut
commensal species can beneﬁt the host by not just conferring
tolerance to themselves but also creating a more generally
tolerant environment by induction of T(reg) cells.
Other bacteria such as Lactobacilli and Biﬁdobacteria have
been proposed to induce T(reg) cells. Treatment of mice with
these probiotic bacteria or other strains of Lactobacillus
increase T(reg) cell abundance [39]. Bacteroides fragilis is a
human gut commensal that, through TLR2 ablation in CD4+ T
cells study in mice, activates TLR2 receptors in naive T-cells to
induce their differentiation toward the T(reg) cells [40]. The
key factor in induction of T(regs) has been found to be the
polysaccharide A (PSA) produced by B. fragilis that allows this
tolerance to be induced. Furthermore, lack of PSA induces the
Th17 axis that prevents successful colonization of these
tolerance-inducing bacteria [40]. This evidence suggests that
the immune system can recognize pathogens from the
commensals and as a by-product receive regulation of
immune homeostasis.
4.3. IgA of B-cells
Intestinal mucosa is a large site of immunoglobulin A (IgA)
production where it plays an important role in maintenance of
mucosal homeostasis, especially protecting from pathogenic
bacteria invasion. It is believed that IgA contains bacteria from
invading the lamina propria mucosa (LPM). Although, its role
may be in ﬁghting pathogens, it also appears to control gut
commensal populations [41]. In the GF mice the IgA production
is reduced due to lower levels of plasma cells. Colonizing mice
with fecal ﬂora containing commensal species such as
Alcaligenes can restore the IgA production [42]. Alcaligenes tend
to colonize the Peyer's patches where they can actively interact
with the CD11+ dendritic cells which send signals to lympho-
cytes to induce IgA production. IgA production only increases at
the sites of Alcaligenes colonization and no systemic spillover of
IgA-producing plasma cell induction occurs [42]. As mentioned,
IgA induction has an important role in maintaining immune
homeostasis by controlling gut commensal populations as well
as preventing pathogens from invading the LPM. GF mice
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adaptive immune system (Rag/) tend to have elevated
proinﬂammatory innate immune responses that are associated
with gut inﬂammatory diseases [43]. However, introduction of
hybridized plasma cells which express IgA binding B. thetaio-
taomicron capsular polysaccharide, can balance the commensal
populations so that proinﬂammatory responses are not too
sufﬁciently strong to cause disease [43]. Abolishing IgA
responses in mice have also shown expansion of segmented
ﬁlamentous bacteria (SFB), which have been shown to induce
Th17 mediated autoimmune disease [21,41]. Therefore, gut
commensals have an important role in preventing development
of dysbiosis by controlling their own and neighboring commen-
sal populations through IgA induction as well as protecting the
host from pathogenic colonization.
5. Diseases associated with changes in gut
microbiota and deregulated immune response
In healthy organism, gut microbiota and host immune system
acts symbiotically allowing the balanced induction of protec-
tive responses to antigens and pathogens. However, changes
in diet, abuse of antibiotics, and other environmental factors
contributed to alteration in composition of microbiota result-
ing in the lack of diversity required to keep balanced immune
responses. This caused an antibiotic effect in gut microbiota-
host immune system relationship contributing to the dramatic
rise in autoimmune and inﬂammatory disorders [44,45].
Although there are many conﬁrmed evidences that alterations
in the gut microbiota composition affects immune responses,Table – Changes in the gut microbiota associated with immun
Disease and health
condition
Implicated microbiota Changes
IBD, Crohn's disease
and ulcerative colitis
Actinobacteria, Proteobacteria Increase
Bacteroidetes, Lachnospiraceae Decreas
IBD, Crohn's disease Bacteroides ovatus, Bacteroides
vulgatus
Increase
Bacteroides uniformis Decreas
Faecalibacterium prausnitzii 
Coeliac disease Bacteroides, Escherichia coli Increase
Rheumatoid arthritis Bacteroides (Prevotella copri) Increase
Encephalomyelitis Alteration of gut microﬂora
after antibiotic treatment
Decreas
Allergy Biﬁdobacterium adolescentis Decreas
Lactobacillus spp. 
Autism Firmicutes (Clostridium) Increase
Gastric cancer Helicobacter pylori Increase
Obesity Bacteroidetes Decreas
Lactobacilus Increase
Type 2 diabetes Firmicutes (Clostridia) Decreas
Escherichia coli Increase
a Changes relative to the healthy subject.
b One exemplary reference is provided.it is also becoming increasingly apparent that such changes
can affect negatively the immunity in organs and tissues distal
from the intestine [46]. Typical cases characterizing the gut
microbiota changes associated with immune response-related
diseases are summarized in Table.
A number of studies have shown that primary IBD, Crohn's
disease (CD), and ulcerative colitis (UC) are associated with a
decreased complexity of the gut microbiota and shift to the
dysbiosis [44]. Both CD and UC were characterized by depletion
of the phyla Firmicutes (predominantly Costridia class Lachnos-
piraceae family) and Bacteroidetes and by outgrowth of the
phylum Proteobacteria (Enterobacteriaceae family) [47]. The CD
has also been associated with such pathogens as Clostridium
difﬁcile and Escherichia coli [59,60], while colitis has been linked
with commensals Helicobacter hepaticus and Bacteroides [61,62],
which all have shown to be important contributors to IBD in
mouse models. Notably, some commensal bacteria with
enhanced inﬂammatory potential are closely related to
pathogens allowing their survival under tough immune
response conditions, and thus contribute to disease by
promoting innate and adaptive immune responses to other-
wise benign commensals or food antigens [63–65]. Role of gut
microbiota has also been implicated in several other autoim-
mune diseases (coeliac disease, rheumatoid arthritis and
encephalomyelitis), as well as allergies, autism, gastric cancer,
obesity and type 2 diabetes (Table).
To date, the majority of research ﬁndings that focused on
how the gut microbiota is contributing to host immune system
related disease have mainly been tested on mouse models and
it is not completely understood whether acquired knowledge
can be directly applied to humans.e response-related diseases and health conditions.
a Relevant
referenceb
Potential preventative measures
 [47] Clostridia and SCFA can induce directly
T(reg)s opposing intestinal inﬂammation
and colitis induction [34,48]
e
 [49]
e
[50]
 [51]
 [52]
e [53] Polysaccharide A produced by Bacteroides
fragilis can protect against central nervous
system demyelinating disease [53]
e [54]
[40]
 [55] Human commensal Bacteroides fragilis
corrects gut permeability, alters microbial
composition and ameliorates autism
spectrum disorder-related defects [55]
 [56]
e [57]
e [58]
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As discussed above, the host-commensal interactions are very
complex and designing a right combination of these bacteria to
tackle disease is very difﬁcult. Gut commensals can directly
and indirectly limit pathogen growth. Infection by C. difﬁcile is a
common type of hospital acquired infections due to their
resistance to cleaning agents and antibiotics. Using the
concept that commensals can limit pathogenic infections, a
double blind, and placebo controlled study examined the role
of probiotics containing Lactobacillus and Biﬁdobacterium [66].
The study showed that toxins produced by the pathogen were
less frequently present among patients that were taking this
probiotic than amongst those who did not. Furthermore, fecal
transplants have become a viable option in treating Clostridi-
um-associated diseases which attenuate their pro-inﬂamma-
tory effects [67–69].
The protective effect of some bacterial species such as
Barnesiella has been also conﬁrmed in cases of broad antibiotic
treatment [9], where intestinal microbiota was dominated
with vancomycin-resistant enterococcus, a pathogen causing
infections in immunocompromised patients [70].
Our knowledge that TLR9 pathway activation in epithelial
cells leads to anti-inﬂammatory milieu [13], which can
alleviate inﬂammation inducing infections [14]; this makes
it possible to potentially exploit it for therapeutic purposes.
TLR2/ and TLR4/ mouse model of colitis presented with
E. coli CpG DNA fragments showed a decrease in disease
progression. This positive effect of probiotics has been
conﬁrmed using the whole bacteria [71,72]. TLR9/ mice
were used to conﬁrm that TLR9 receptors were crucial for anti-
inﬂammatory actions of probiotics.
7. Concluding remarks
There are an increasing number of studies that attempt to
describe gut commensal and host immune interactions. At the
moment, it is clear that gut microbiota greatly contributes to
the metabolic and immune homeostasis and inﬂuence health
and disease. Gut commensals are essential for healthy
metabolic function and their altered composition does
correlate with various metabolic issues. A list of autoimmune
diseases, many appearing outside of the gut, is also correlated
to the dysbiosis [73]. Although, the evidence may suggest that
the gut commensals can be beneﬁcial and harmful, the
complex host environment affects this friend or foe status
to a large extent. Gut commensals, like any bacteria, whether
pathogenic or not, are only concerned with their own
wellbeing and do not differentiate between the host's health
and its disease. Their survival depends on the symbiotic
relationship. However, changes in the host environment (due
to genetic or other environmental factors) can quickly reverse
gut commensal role or it may disable them from surviving
under new conditions. This may result in the host losing an
important service, which in turn may lead to disease. It is
difﬁcult to determine whether the changes in commensal
composition are a primary cause of disease. Therefore, further
understanding of the mechanisms of microbial interactionswith the host is crucial for future therapeutic uses of the gut
commensal manipulation.
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